Clascoterone (Winlevi) cream was safe and effective for up to 12 months in patients with acne ages 12 and older, and may in fact become more efficacious over time.
That's according to results of an extension study that appears in the Journal of Drugs in Dermatology.
Enrolled patients applied clascoterone cream 1% twice daily to the entire face and, if desired by the patient and/or investigator, truncal acne, for up to 9 months.
Patients achieving Investigator's Global Assessment score of 0 or 1 (IGA 0/1) could stop and resume treatment if needed. Of 600 patients ages 12 and older (original randomization: 311 clascoterone, 289 vehicle) included in the original study, 343 completed the extension study (177 clascoterone, 166 vehicle).
Participants reported 187 adverse events in 108/598 clascoterone-treated patients (18.1%); these affected 56/311 (18.0%) and 52/287 (18.1%) patients originally randomized to clascoterone and control groups, respectively. The percentage of patients with facial and truncal IGA 0/1 increased to 48.9% (156/319) and to 52.4% (65/124), respectively, among those who completed the study per protocol.
The study was conducted by a team of U.S.-based researchers, including first author Lawrence Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego and professor of dermatology and pediatrics and vice-chair of the department of dermatology at University of California San Diego School of Medicine. The following study excerpts have been lightly edited for length and clarity.
What was the key objective of this trial?
Clascoterone cream 1%, a novel topical androgen receptor inhibitor, was approved in the U.S. in 2020 for the treatment of acne vulgaris in males and females ages 12 years and older.
The cream's efficacy and safety were assessed in two identical Phase 3 clinical trials and in a long-term extension study in patients ages 9 and older with moderate-to-severe acne vulgaris. In the Phase 3 pivotal studies, treatment with clascoterone cream 1% resulted in significant clinical improvement compared with vehicle cream after 12 weeks of twice-daily application, with a favorable safety profile.
Clascoterone safety was well maintained for up to an additional 9 months of treatment in patients ages 9 and older with moderate-to-severe acne vulgaris. Here, the study team presented long-term safety and efficacy data in the subgroup of clinical trial patients ages 12 and older who entered the long-term extension study.
What were the key findings?
This 9-month extension study confirmed the favorable safety profile of clascoterone cream 1% in the long-term treatment of patients ages 12 and older with moderate-to-severe facial and/or truncal acne vulgaris. The frequencies of treatment-emergent adverse events (TEAE) and local skin reactions were low throughout the study. Most of the TEAEs were mild, and no accumulation of adverse events was observed over time.
The proportions of patients with facial and truncal IGA 0/1 increased over time and were highest at the end of the study, indicating that clascoterone efficacy continued to increase with long-term treatment. These results suggest that clascoterone may be a suitable option for long-term topical treatment of both facial and truncal acne vulgaris in patients in this age group.
What was the safety profile after the extension period?
Overall, 108/598 (18.1%) patients in the safety population experienced a total of 187 TEAEs; frequency was similar between patients previously treated with clascoterone (56/311 [18.0%]) versus vehicle (52/287 [18.1%]). Most TEAEs were mild or moderate and not considered related to clascoterone treatment.
A total of 6/598 (1.0%) patients reported serious adverse events, none of which were considered related to clascoterone treatment; 9/598 (1.5%) patients had TEAEs leading to study discontinuation. The most frequent TEAEs by percentage of patients affected included nasopharyngitis (17 [2.8%]), upper respiratory tract infection (11 [1.8%]), sinusitis (5 [0.8%]), viral respiratory tract infection (5 [0.8%]), and application site acne (4 [0.7%]) among all patients.
What are the key takeaways for dermatologists?
This and previous studies support clascoterone as an option for long-term treatment of acne vulgaris.
The proportion of patients whose skin was clear or almost clear increased at each visit and was highest at the end of the study, indicating that clascoterone efficacy improved over time for up to 12 months in patients with moderate-to-severe acne vulgaris.
Eichenfield is an employee of the University of California San Diego, which received compensation from Cassiopea S.p.A., for study participation; he also reports relationships with Almirall, Dermata, Galderma Laboratories, and Ortho Dermatologics.
Here is the original post:
Clascoterone Cream in Patients With Acne: New Long-Term Data - Medpage Today
- AAD 2025: Galderma to Present Extensive Updates From Across Its Dermatology Portfolio, Demonstrating Its Category Leadership and Strong Momentum -... - March 5th, 2025 [March 5th, 2025]
- What to Look Forward to at the American Academy of Dermatology Annual Meeting 2025 - MD Magazine - March 5th, 2025 [March 5th, 2025]
- Recognizing the Achievements of Women in Dermatology - Dermatology Times - March 5th, 2025 [March 5th, 2025]
- The Solar Spectrum and Impact on Skin Health - Dermatology Times - March 5th, 2025 [March 5th, 2025]
- The Undetectable Era: How Patients Are Shifting Towards More Natural-Looking Results at the Clinic - Dermatology Times - March 5th, 2025 [March 5th, 2025]
- Researchers overseas: Radiology has become indispensable to dermatology - Radiology Business - March 5th, 2025 [March 5th, 2025]
- Defining Alopecia Areata Severity and Navigating Treatment Options - Dermatology Times - March 5th, 2025 [March 5th, 2025]
- Acne and TikTok: What Do Dermatologists Need to Know? - Dermatology Times - March 5th, 2025 [March 5th, 2025]
- Celebrating Womens History Month with Mindy Haws, MD, and the LIMITLESS Initiative - Dermatology Times - March 5th, 2025 [March 5th, 2025]
- A Case-Based Approach to Topical and Nonsteroidal AD Management - Dermatology Times - March 5th, 2025 [March 5th, 2025]
- Dermatology Partners Opens State-of-the-Art Dermatopathology Laboratory - citybiz - February 25th, 2025 [February 25th, 2025]
- Ethical Considerations and Guidance of Cosmeceuticals in Pediatric Care - Dermatology Times - February 25th, 2025 [February 25th, 2025]
- AI in Dermatology: Emerging Insights and Diverging Perspectives - MD Magazine - February 25th, 2025 [February 25th, 2025]
- Almirall 2024 Full-Year Results: Almirall Surpassed Guidance for 2024 - Entering an Era of Sustained Growth and Further Advancing Its Medical... - February 25th, 2025 [February 25th, 2025]
- Aesthetic Treatments: More Than Just Enhancements, A Path to Empowerment - Dermatology Times - February 25th, 2025 [February 25th, 2025]
- Samitivej to advance dermatology and aesthetic medicine in new partnership - Healthcare Asia - February 25th, 2025 [February 25th, 2025]
- Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with... - February 25th, 2025 [February 25th, 2025]
- U.S. Dermatology Partners Ranked the No. 1 Dermatology Group in the Nation by Castle Connolly - PR Newswire - February 3rd, 2025 [February 3rd, 2025]
- Alopecia Areata Risk May be Associated With Serum Vitamin D and Zinc Levels - Dermatology Advisor - February 3rd, 2025 [February 3rd, 2025]
- Age at Melanoma Diagnosis Varies by Sex, Anatomic Site, and Tumor Thickness - Dermatology Advisor - February 3rd, 2025 [February 3rd, 2025]
- Dermatology Medications and Solutions Market Poised to Growth USD 51.7 Billion by 2032 with Thriving CAGR of - EIN News - January 23rd, 2025 [January 23rd, 2025]
- Optimizing Care for Patients with Urticaria - Dermatology Times - January 23rd, 2025 [January 23rd, 2025]
- Advancing Care With Laser and Light-Based Technology in Dermatology - Dermatology Times - January 23rd, 2025 [January 23rd, 2025]
- Online Dermatology Consultation Market: CAGR of 15.4% Expected by 2025 Due to Increasing Skin Health Awareness - openPR - January 23rd, 2025 [January 23rd, 2025]
- VP-315 Demonstrates Positive Topline Results in Basal Cell Carcinoma - Dermatology Times - January 23rd, 2025 [January 23rd, 2025]
- AI and the Future of Cosmetic Dermatology: Experts Weigh in - Medscape - January 23rd, 2025 [January 23rd, 2025]
- When and How to Employ the Buy and Bill Model - Dermatology Times - January 23rd, 2025 [January 23rd, 2025]
- Innovating Scalp Care: How Research and Education Drive Solutions - Dermatology Times - January 15th, 2025 [January 15th, 2025]
- Rare Overlap of 2 Autoinflammatory Keratinization Diseases Observed in Single Lesion - Dermatology Times - January 15th, 2025 [January 15th, 2025]
- Expanding Laser Benefits for Diverse Patient Populations - Dermatology Times - January 15th, 2025 [January 15th, 2025]
- LEO Pharma and Gilead Will Develop STAT6 Program for AD and Other Inflammatory Diseases - Dermatology Times - January 15th, 2025 [January 15th, 2025]
- Kwon Min-ah, a former member of the group AOA, became the head of the dermatology consultation offic.. - - January 15th, 2025 [January 15th, 2025]
- Top 5 Dermatology Articles of 2024 - Managed Healthcare Executive - January 1st, 2025 [January 1st, 2025]
- DEI programs, sun safety: Read this years top practice management articles in dermatology - Healio - January 1st, 2025 [January 1st, 2025]
- Cutaneous Connection 2024: Top Dermatology Podcast Episodes and Insights of the Year - Dermatology Times - January 1st, 2025 [January 1st, 2025]
- Top Insights and Highlights from Dermatology Times' Interview Intersection: 2024 - Dermatology Times - January 1st, 2025 [January 1st, 2025]
- Providing Support for Comorbidities and Psychological Health in Patients with Atopic Dermatitis - Dermatology Times - January 1st, 2025 [January 1st, 2025]
- Reviewing Major Dermatologic Studies of the Year: 2024 - Dermatology Times - January 1st, 2025 [January 1st, 2025]
- Peak Dermatology in Visalia hopes to provide more skin services and treatment to the area - KFSN-TV - December 23rd, 2024 [December 23rd, 2024]
- Krystal Tawney of Pinnacle Dermatology celebrates 10 years of business in the Greenbrier Valley - Real WV - December 23rd, 2024 [December 23rd, 2024]
- Supporting Pediatric Patients With AD and Their Caregivers - Dermatology Times - December 23rd, 2024 [December 23rd, 2024]
- Photodynamic Therapy is an Effective, Long-Term Treatment for Actinic Keratosis - Dermatology Times - December 23rd, 2024 [December 23rd, 2024]
- InflaRx Advances INF904 for CSU and HS with Phase 2a Study - Dermatology Times - December 23rd, 2024 [December 23rd, 2024]
- Advanced Dermatology to pay $15G fine after doctor refused to perform procedure on HIV-infected patient - Newsday - December 9th, 2024 [December 9th, 2024]
- Efficacy of Combining Postbiotic Formulation with Microneedling for Acne - Dermatology Times - December 9th, 2024 [December 9th, 2024]
- Burden of Hidradenitis Suppurativa on Patients and Diagnostic Challenges - Dermatology Times - December 9th, 2024 [December 9th, 2024]
- Opioid-Prescribing Trends in Dermatology From 2014 to 2020 in the United States - Cureus - November 28th, 2024 [November 28th, 2024]
- Amid challenges, the Baton Rouge dermatology industry is evolving - Greater Baton Rouge Business Report - November 28th, 2024 [November 28th, 2024]
- Polynucleotide Therapy Shows Promise in Scar and Burn Management - Dermatology Times - November 28th, 2024 [November 28th, 2024]
- Revolutionizing Dermatology: How Emerging Technologies are Shaping the Future of Skin Care - Spherical Insights - November 28th, 2024 [November 28th, 2024]
- Dermatology OTC Medications Market Size, Scope Analysis, Key Insights, Leading Key Players, And Forecast To 2033 - openPR - November 28th, 2024 [November 28th, 2024]
- Jeff Stark, MD: Insights on the Approval of Bimekizumab for HS - Dermatology Times - November 28th, 2024 [November 28th, 2024]
- Exploring the Atopic Dermatitis Treatment Paradigm and Challenging Cases: Part 2 - Dermatology Times - November 28th, 2024 [November 28th, 2024]
- Patient Education and Novel Topical Therapies for AD - Dermatology Times - November 28th, 2024 [November 28th, 2024]
- TikTok dermfluencers have medical students flocking to dermatology, where they can make half a million dollars a year and work four days a week -... - November 20th, 2024 [November 20th, 2024]
- $500,000 Pay, Predictable Hours: How Dermatology Became the It Job in Medicine - The Wall Street Journal - November 20th, 2024 [November 20th, 2024]
- Empowering Dermatology PAs Through Education and Career Support - Dermatology Times - November 20th, 2024 [November 20th, 2024]
- U.S. Dermatology Partners Announces the Opening of Stephenville, Texas Office - PR Web - November 20th, 2024 [November 20th, 2024]
- $500,000 Pay, Predictable Hours: How Dermatology Became the It Job in Medicine - Yahoo! Voices - November 20th, 2024 [November 20th, 2024]
- FRONTIER-2 Study Evaluates Safety and Efficacy of Tozorakimab in Patients with AD - Dermatology Times - November 20th, 2024 [November 20th, 2024]
- Improving Care and Innovations in Vitiligo and Atopic Dermatitis: Part 1 - Dermatology Times - November 20th, 2024 [November 20th, 2024]
- In the United States, the dermatology concentration of doctors is also noticeable.The Wall Street Jo.. - - November 20th, 2024 [November 20th, 2024]
- Dermatology Diagnostic Devices and Therapeutics Market Size, Trends and Industry Growth Forecast to 2032 - openPR - November 20th, 2024 [November 20th, 2024]
- POLL: What Topics Are You Looking Forward to at SDPA Fall 2024? - Dermatology Times - November 20th, 2024 [November 20th, 2024]
- Digital tool aims to tackle long dermatology waits - Health and Care News Scotland - November 20th, 2024 [November 20th, 2024]
- Is AI Coming for My Job?: Familiarizing Clinicians with AI Tools and Their Role in Dermatology - Dermatology Times - November 12th, 2024 [November 12th, 2024]
- Almiralls Nine-Month 2024 Results: Almirall Reports Strong Performance at Q3 2024 - Driven by Successful Commercial Execution of the Dermatology... - November 12th, 2024 [November 12th, 2024]
- Updates on the Latest Cosmetic Treatments in Medical Care - Dermatology Times - November 12th, 2024 [November 12th, 2024]
- Jenny Murase, MD: Emerging Therapies Bring Hope to Patients with Persistent Itch - Dermatology Times - November 12th, 2024 [November 12th, 2024]
- POLL: Are You Attending the Elevate-Derm West Conference? - Dermatology Times - November 12th, 2024 [November 12th, 2024]
- Memorial Health System is re-opening of Department of Dermatology - Parkersburg News - October 26th, 2024 [October 26th, 2024]
- Available Therapeutics and Upcoming Advancements in Atopic Dermatitis and Prurigo Nodularis - Dermatology Times - October 26th, 2024 [October 26th, 2024]
- Sun Pharma Announces Multiple Data Presentations Highlighting its Dermatology Portfolio to be Featured at the 2024 Fall Clinical Dermatology... - October 26th, 2024 [October 26th, 2024]
- What To Look Forward To at the Fall Clinical Dermatology Conference, with Raj Chovatiya, MD, PhD - MD Magazine - October 26th, 2024 [October 26th, 2024]
- Navigating Complexities and Unmet Needs of Chronic Hand Eczema - Dermatology Times - October 26th, 2024 [October 26th, 2024]
- Schweiger Dermatology Group Expands in Florida with the Acquisition of ClearlyDerm, Adding 5 New Offices in South Florida - PR Newswire - October 26th, 2024 [October 26th, 2024]
- Leo Pharma tells doctors to 'Talk to the Hand' in new dermatology campaign - FiercePharma - October 26th, 2024 [October 26th, 2024]
- Dermatology Partners To Expand Maryland Presence With New Westminster Clinic, Hosts Free Skin Cancer Screenings For Veterans On November 11 - citybiz - October 26th, 2024 [October 26th, 2024]
- Peter Lio, MD: The Latest Perspectives on Pathophysiology and Treatment of Eczema - Dermatology Times - October 26th, 2024 [October 26th, 2024]
- Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell... - October 26th, 2024 [October 26th, 2024]